LY 3303560

Drug Profile

LY 3303560

Alternative Names: LY3303560

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antidementias
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 13 Jan 2017 Eli Lilly initiates a phase I trial in Alzheimer's disease in USA (NCT03019536)
  • 13 Jan 2017 Eli Lilly plans a phase I trial in Alzheimer's disease in Japan and the United Kingdom (NCT03019536)
  • 29 Apr 2016 Preclinical trials in Alzheimer's disease in USA (IV and SC) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top